Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple Turns 50: From Garage Startup to AI Crossroads 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
WALTHAM, Mass., June 29, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as the Presenting Sponsor of the 2017 Ovarian Cancer National Conference, being held July 7-9 in Chicago, IL. The OCRFA National Conference is the largest and longest-running conference for women living with ovarian cancer and their caregivers, bringing together more than 400 survivors, caregivers, researchers, and advocates to hear about the latest innovations in ovarian cancer, find hope and inspiration, and support ovarian cancer awareness initiatives.
“Our annual conference is an opportunity to provide much needed education on cutting-edge developments in diagnosis, treatment and quality of life to women with ovarian cancer and their caregivers,” said Audra Moran, President & CEO of Ovarian Cancer Research Fund Alliance. “We are excited to partner with TESARO on our flagship conference and look forward to continued collaboration in the future.”
“Driven by a deep appreciation for patient needs, TESARO is committed to not only supporting, but truly partnering with women living with ovarian cancer,” said Lonnie Moulder, CEO of TESARO. “Patients are at the center of all that we do, and we are thrilled to join forces with OCRFA to support the 2017 Ovarian Cancer National Conference and be a part of this life-changing experience for survivors and caregivers.”
For more information about the Ovarian Cancer National Conference, please visit https://conference.ocrfa.org.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
Investor/Media Contact: Jennifer Davis Vice President, Corporate Affairs & Investor Relations +1.781.325.1116 or [email protected]
